Anifrolumab, a relatively recent monoclonal protein, is creating considerable interest within the medical community as a viable option for various inflammatory disorders. This unique medication targets the interferon https://sabrinacukn693905.activoblog.com/51909081/anifrolumab-a-promising-approach-for-autoimmune-conditions